| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
7,3',4'-Trihydroxyisoflavone targets multiple proteins and pathways. It acts as an ATP-competitive inhibitor of the serine/threonine kinases Cot (Tpl2/MAP3K8) and MKK4. Additionally, it directly targets the melanocortin 1 receptor (MC1R). It also modulates the activity of enzymes like tyrosinase (IC50 = 5.2 µM) and influences signaling pathways involving NF-κB, AKT, p38, and PKA. Furthermore, it has been shown to modulate multidrug resistance transporters.
|
|---|---|
| ln Vitro |
7,3',4'-Trihydroxyisoflavone exerts antiproliferative effects on skin cancer that is positive for the EGF receptor and causes cell cycle arrest in the G1 phase [1]. Moreover, 7,3',4'-Trihydroxyisoflavone dramatically reduces UVB-induced COX-2 expression in mouse skin epidermal JB6 P+ cells by blocking NF-B transcriptional activity [1].
In vitro, 7,3',4'-Trihydroxyisoflavone demonstrates significant biological activity. It exerts antiproliferative effects on EGF receptor-positive skin cancer cells and triggers cell cycle arrest at the G1 phase. It dramatically reduces UVB-induced COX-2 expression by blocking NF-κB transcriptional activity in mouse skin epidermal JB6 P+ cells. It inhibits α-MSH-induced melanogenesis in B16F10 cells and human epidermal melanocytes by targeting MC1R. It also shows DPPH radical scavenging activity with an IC50 of 28.7 µM. |
| ln Vivo |
7,3',4'-trihydroxyisoflavone significantly reduced the frequency, number, and size of UVB-induced mouse skin tumors in a model of skin tumorigenesis. 7,3',4'-trihydroxyisoflavone significantly reduced UVB-induced COX-2 expression in the skin of hairless mice, in agreement with tumor data [2].
In vivo, 7,3',4'-Trihydroxyisoflavone has demonstrated efficacy in several animal models. Topical application significantly suppressed the incidence, number, and size of UVB-induced skin tumors in hairless mouse skin. It also significantly reduced UVB-induced COX-2 expression in the skin of hairless mice. Furthermore, oral administration improved learning and memory in mice by regulating the cholinergic system and BDNF signaling. It has also been detected as an in vivo metabolite of daidzein in humans. |
| Enzyme Assay |
In vitro enzyme inhibition assays are used to study the compound's mechanism. Kinase assays with Western blotting show that 7,3',4'-THIF inhibits Cot and MKK4 activity, suppressing UVB-induced phosphorylation of mitogen-activated protein kinases. Pull-down assays indicate it competes with ATP to inhibit Cot or MKK4 activity. For MC1R binding, pull-down assays and cAMP production inhibition assays are used. Tyrosinase inhibition is measured using standard enzymatic assays (IC50 = 5.2 µM), and antioxidant activity is assessed via DPPH radical scavenging assays.
|
| Cell Assay |
In vitro cellular assays are performed in various cell lines. Mouse skin epidermal JB6 P+ cells are used to study the inhibition of UVB-induced COX-2 expression and NF-κB transcriptional activity. B16F10 melanoma cells and human epidermal melanocytes (HEMs) are used to assess anti-melanogenic effects by measuring melanin production and related protein expression. HepG2 cells are used to evaluate anti-cancer activity under hypoxic conditions. The compound's effects on cell proliferation, cell cycle, and apoptosis are typically assessed using MTT assays, flow cytometry, and Western blotting.
|
| Animal Protocol |
In vivo animal studies have been conducted in mouse models. For skin cancer studies, hairless mice are treated topically with the compound followed by UVB irradiation, and tumor incidence and multiplicity are assessed. COX-2 expression in skin is also evaluated. For cognitive function studies, mice are administered the compound orally, and memory is evaluated using Y-maze and passive avoidance tests. The compound has also been identified as a metabolite in in vivo studies following the administration of daidzein.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for 7,3',4'-Trihydroxyisoflavone are limited. As a metabolite of daidzein, its properties are related to the parent compound's metabolism. Daidzein is metabolized by cytochrome P450 enzymes, including CYP1A2, CYP1A1, and CYP1B1, to form 7,3',4'-trihydroxyisoflavone. The compound has a topological polar surface area of 87 Ų. It is soluble in DMSO at concentrations up to 2.08 mg/mL (7.70 mM). In silico predictions suggest favorable drug-likeness and pharmacokinetic properties.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 7,3',4'-Trihydroxyisoflavone indicates it can cause oxidative DNA damage through a metal-dependent mechanism, enhanced by the presence of NADH. It induces apoptosis in cancer cells via the production of reactive oxygen species (ROS). The compound is for research use only and is not intended for human therapeutic use. Standard safety data are not extensively reported, but it should be handled with care in a laboratory setting.
|
| References |
|
| Additional Infomation |
3',4',7-Trihydroxyisoflavone is a 7-hydroxyisoflavone, a derivative of daidzein with a hydroxyl group substituted at the 3' position. It possesses metabolites, antitumor activity, and is an EC 1.3.1.22 [3-oxo-5α-steroidal 4-dehydrogenase (NADP(+))] inhibitor. Its function is related to daidzein. 3',4',7-Trihydroxyisoflavone has been reported to exist in Dalbergia spruceana, Hibiscus syriacus, and other organisms with relevant data.
7,3',4'-Trihydroxyisoflavone (CAS 485-63-2, Cat. No.: V46955) is a naturally occurring isoflavonoid and a primary metabolite of the soy isoflavone daidzein. It is a potent, multi-targeting compound with anticancer, anti-angiogenic, chemoprotective, antioxidant, and anti-melanogenic activities. Its mechanism of action involves ATP-competitive inhibition of Cot and MKK4, as well as direct targeting of MC1R. The compound has shown efficacy in preclinical models of skin cancer and cognitive enhancement. It is not an approved drug and is available for research purposes only. |
| Molecular Formula |
C15H10O5
|
|---|---|
| Molecular Weight |
270.2369
|
| Exact Mass |
270.052
|
| CAS # |
485-63-2
|
| PubChem CID |
5284648
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
572.8±50.0 °C at 760 mmHg
|
| Melting Point |
280-282°C
|
| Flash Point |
224.0±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.732
|
| LogP |
2.58
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
419
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DDKGKOOLFLYZDL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O5/c16-9-2-3-10-14(6-9)20-7-11(15(10)19)8-1-4-12(17)13(18)5-8/h1-7,16-18H
|
| Chemical Name |
3-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~370.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7004 mL | 18.5021 mL | 37.0041 mL | |
| 5 mM | 0.7401 mL | 3.7004 mL | 7.4008 mL | |
| 10 mM | 0.3700 mL | 1.8502 mL | 3.7004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
